Got back pain questions? Our Back Wellness Coaches have answers. Text Us Now at 412.419.2225. It's FREE!

Login Signup

DiscGenics’ Japanese clinical trial of DDD cell therapy treats first patients

Published August 14, 2019

DiscGenics is engaged in developing regenerative cell-based therapies to relieve pain and reinstate function in patients with degenerative diseases of the spine. DiscGenics, a clinical stage biotechnology company, announced the first patients have been treated in its Japanese safety study, a clinical trial of Injectable Disc Cell Therapy (IDCT) for mild to moderate degenerative disc disease (DDD). 

Full Article
Last change: August 14, 2019


Loading Feed

Whichever company can successfully develop this type of technology with long-term results will help tens of millions of people year avoid pain and future surgeries. I'm rooting for every company in this space right now.I hope they all get it right.

. 0 Comment  Comment